title: Effects of high doses of A-74273, a novel nonpeptidic and orally bioavailable renin inhibitor.
abstract: Previous studies with peptidic renin inhibitors have shown that high intravenous (i.v.) doses can induce unexpectedly large decreases in blood pressure (BP) that appear to be independent of plasma renin inhibition. A-74273 represents a new class of potent and orally bioavailable nonpeptidic renin inhibitors. We evaluated the BP effects of this renin inhibitor administered orally (p.o.) or i.v. at high doses to conscious salt-depleted dogs. Administration of A-74273 at 30 and 60 mg/kg p.o. (n = 6 per dose) produced similar maximum reductions in BP (-40 +/- 4 vs. -46 +/- 5 mm Hg) despite the occurrence of greater plasma drug concentrations at the higher dose. Duration of hypotension, however, was increased (p < 0.05) from 9 h at 30 mg/kg to 18 h at 60 mg/kg. The initial depressor response to 10 and 30 mg/kg i.v. doses of A-74273 (n = 6 per dose) was comparable, although duration and overall BP response was greater at 30 mg/kg i.v. No BP responses to A-74273 were noted in salt-replete dogs (n = 5). The hypotension produced by 30 mg/kg p.o. A-74273 was completely reversed by norepinephrine (NE 5 micrograms/kg/min; n = 5) or isotonic saline (4 ml/min/kg, n = 5) infusion. These studies demonstrate that high doses of A-74273 result in predictable BP responses that are renin-dependent and reversible. Therefore, large decreases in BP with high doses is not an attribute common to all renin inhibitors but appears to be a function of the structural characteristics specific to a particular compound.
authors.affiliation: Abbott Laboratories, Cardiovascular Research Division, Abbott Park, IL 60064.
authors.forename: K M
authors.initials: KM
authors.lastname: Verburg
authors.forename: J S
authors.initials: JS
authors.lastname: Polakowski
authors.forename: P J
authors.initials: PJ
authors.lastname: Kovar
authors.forename: V
authors.initials: V
authors.lastname: Klinghofer
authors.forename: J L
authors.initials: JL
authors.lastname: Barlow
authors.forename: H H
authors.initials: HH
authors.lastname: Stein
authors.forename: R A
authors.initials: RA
authors.lastname: Mantei
authors.forename: A K
authors.initials: AK
authors.lastname: Fung
authors.forename: S A
authors.initials: SA
authors.lastname: Boyd
authors.forename: W R
authors.initials: WR
authors.lastname: Baker
mesh_terms: D000284:Administration, Oral; D000577:Amides / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D000818:Animals; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects*; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D009025:Morpholines / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology; D012083:Renin / Q000097:blood; D014661:Vasoconstriction / Q000187:drug effects; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D009025:Morpholines; D009638:Norepinephrine; D012083:Renin; D000092502:Renin Inhibitors; C078248:A 74273